Mohammad Javad Nasiri, Abbas Ali Imani Fooladi, Hossein Dabiri, Ali Pormohammad, Alireza Salimi Chirani, Masoud Dadashi, Hamidreza Houri, Mohsen Heidary, Mohammad Mehdi Feizabadi
INTRODUCTION: Ethambutol (EMB) is an anti-mycobacterial agent that is most commonly used in combination with other anti-tuberculosis (TB) drugs in the treatment of TB. Studies have shown that primary resistance rates of Mycobacterium tuberculosis to EMB vary widely, that is, from 1% to as high as 14%. In this study, we aimed to determine the exact prevalence of primary EMB resistance among pulmonary TB cases. METHODS: Several databases, including Medline, Embase, and Iranian databases, were searched from March 2000 to January 2016 to identify studies addressing EMB-resistant TB in Iran...
October 2016: Therapeutic Advances in Infectious Disease